

Patient-Relevant Bleeding Events Among Patients Taking Anticoagulant Medication

Presenting author: Dan Bloomfield, MD

Co-authors: B Alexander Yi, Karen Lipworth, Steve Burrows, Mellanie True Hills, Tarin Patrikis, Karen Pieper, Marc P. Bonaca, John Glasspool

Anthos Therapeutics, Inc.; Insocius; StopAfib.org, American Foundation for Women's Health; National Blood Clot Alliance; Thrombosis Research Institute; CPC Clinical Research and University of Colorado School of Medicine

Abstract ID: 1441167 Oral presentation: OC 21.4





• I am an employee of and have a financial stake in Anthos Therapeutics [privately held company]



Learning objectives

Understand the day-to-day bleeding problems (defined as bleeding not requiring medical intervention) experienced by patients on anticoagulants, and the impact on daily activities, emotional well-being, and adherence

Review key results from a global survey on the impact of *patient-relevant bleeding* (PRB) events, including questions about their experiences, the effect on their emotions, and how it made them feel about their anticoagulant therapy.



The impact of bleeding events on quality of life for patients taking anticoagulation is not well studied

- Bleeding events or bruising that do not require medical intervention are often referred to as "minor" bleeding events, but even minor bleeds may be relevant to patients
- The term "minor" may also reduce HCP-patient communication on this type of bleeding
- We suggest using the term patient-relevant bleeding (PRB) events instead of 'minor' bleeding
- The impact of these PRB events among patients taking anticoagulant medications is underreported, poorly understood, and has not been well described

The objectives of this study were to explore the impact of PRB events in patients taking anticoagulants on:

- Daily activities
- Emotional well-being
- Adherence



Global survey of 3,000+ patients prescribed anticoagulants






Under the leadership of **StopAfib.org** and the **National Blood Clot Alliance (NBCA)**, a comprehensive patient questionnaire intended to gain quantitative and qualitative insight on the impact of Patient-Relevant Bleeding (PRB) events, which we defined as bleeding not requiring medical intervention.

Aims of Patient Survey: To explore the impact of PRB events on daily activities, emotional well-being, and adherence in patients taking anticoagulants


- Participants aged ≥21 years currently taking anticoagulants were included (warfarin, low molecular weight heparin, or direct oral anticoagulant)
- The online survey was made available in November 2022 and is accessible globally (English language only)
- · No personally identifiable information collected






Bleeding problems reported across multiple diagnoses, with AF patients experiencing the highest rates

Patient-reported diagnosis (patients may report more than one, n=3,072)



66% of patients were \geq 65 years of age

86% of those with a bleeding problem experienced both bleeding and bruising



On average patients reported experiencing 3.3 of the specified types of bleeds or bruising since starting their current treatment




Base = 3,072 completed the survey of which 1,815 (59%) experience bleeding problems on current treatment. Patients who experienced a bleeding problem completed the full survey to understand the impact of those bleeds Source: Global survey of patients prescribed a blood thinning product, Insocius, Nov 2022

Not experienced bleed


Experienced bleed

59% of patients reported experiencing a bleeding problem since starting an anticoagulant





47% of patients acknowledged bleeding may have an emotional impact



attention heightens the emotional impact

Potential for another clot ۰

.


۲

Base = 1,815 (59%) experiencing a bleeding problem on current treatment Source: Global survey of patients prescribed a blood thinning product. Insocius, Nov 2022

A substantial proportion of patients adjusted their lifestyles to reduce risk or hide bleeding

54% Reported adjusting their lifestyles to reduce risk of bleed

Patients reported they spend less time doing hobbies or traveling and wear clothes to cover marks or bruises Of the 54% of patients who adjusted their lifestyles:




80%

Other reported (<20%):

I have made changes in my work/profession

I usually avoid outdoor activities like swimming where my bruises or marks would be visible to others

Bleeding problems often lead patients to want to pause treatment or reduce their anticoagulant dose



Base = 1,815 (59%) experiencing a bleeding problem on current treatment. Source: Global survey of patients prescribed a blood thinning product, Insocius, Nov 2022.

Conclusion: Patient impact is significant

Survey shows the impact of PRB events on patients' quality-of-life and adherence to anticoagulant therapy

- Patients withdraw from an active, healthy lifestyle to minimize bleeding risk
- Women stay at home during menstrual bleed due to fear of heavy periods
- Patient-reported emotional burden includes fear of a future bleed they are unable to control
- Without informing their HCP, some patients temporarily stop taking their anticoagulant medication
 - Other studies suggest that consequences of poor adherence include a nearly 5X increased risk of thrombotic event but NO decrease in bleeding risk compared to fully adherent patients¹

Instead of referring to these events as "minor", we propose the term "patient-relevant bleeding (PRB)" to more appropriately reflect their impact and clinical significance



Clinical Significance

Need for a new generation of anticoagulants

In patients with atrial fibrillation being treated with an anticoagulant:

- □ Major bleeds are critical, but ALL bleeds matter
- Bleeding and bruising that are relevant to patients, but may not require medical attention, should be considered relevant to the prognosis and clinical care of patients with atrial fibrillation
- Patient-relevant bleeding has a significant impact on the quality of life of patients and may lead to poor adherence, leaving patients at a high risk for experiencing a stroke

These data highlight the need for a new generation of anticoagulants that reduce the risk of stroke and VTE, with substantially less bleeding than the existing agents



Acknowledgments

- Mellanie True Hills (StopAfib.org) and Tarin Patrikis (National Blood Clot Alliance) for facilitating the survey in their respective organizations, and the 3,000+ patients who took the time to complete the survey
- Karen Lipworth and Steve Burrows for the design of the questionnaire and analysis of the results

